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Sunlmary 
Hematopoietins, interleukin (IL)-3, IL-5, and granulocyte/macrophage colony-stimulating factor 
(GM-CSF) have previously been shown to prolong eosinophil survival and abrogate apoptosis. 
The objective of this study was to investigate the effect of transforming growth factor/3 (TGF-B) 
on eosinophil survival and apoptosis. Eosinophils from peripheral blood of mildly eosinophilic 
donors were isolated to >97% purity using discontinuous Percoll density gradient. Eosinophils 
were cultured with hematopoietins with or without TGF-B for 4 d and their viability was assessed. 
We confirmed previous observations that hematopoietins prolonged eosinophil survival and inhibited 
apoptosis.  TGF-/~  at  concentrations  >-10  -12  M  abrogated  the  survival-prolonging  effects of 
hematopoietins in  a dose-dependent manner  and induced apoptosis  as  determined by DNA 
fragmentation in agarose gels. The effect of TGF-3 was blocked by an anti-TGF-3  antibody. 
The anti-TGF-/~ antibody also prolonged eosinophil survival on its own. The culture of eosinophils 
with IL-3 and GM-CSF stimulated the synthesis of GM-CSF and IL-5, respectively, suggesting 
an autocrine mechanism of growth factor production. TGF-3 inhibited the synthesis of GM-CSF 
and IL-5 by eosinophils. TGF-3 did not have any effect on the expression of GM-CSF receptors 
on eosinophils. We also studied the effect of TGF-3 on eosinophil function and found that TGF-3 
inhibited the release of eosinophil peroxidase. Thus, TGF-3 seems to inhibit eosinophil survival 
and function. The inhibition of endogenous synthesis of hematopoietins may be one mechanism 
by which TGF-3 blocks eosinophil survival and induces apoptosis. 
T 
he eosinophil is a short-lived, terminally differentiated 
cell. The death of eosinophils is characterized by DNA 
fragmentation, which is typical of apoptosis (1). The eosino- 
phil is primarily involved in allergic reactions and host de- 
fense against parasites.  Allergic diseases as well as parasitic 
infections are characterized by blood and tissue eosinophilia. 
The tissue eosinophilia is likely the result of increased produc- 
tion of eosinophils in the bone marrow and decreased apop- 
tosis. Hematopoietins, IL-5, IL-3, and GM-CSF, have been 
shown to stimulate production of eosinophils in the bone 
marrow (2). The same cytokines inhibit eosinophilic apop- 
tosis and prolong survival when eosinophils are cultured in 
their presence (3-5).  Mice that are transgenic for IL-5 have 
profound eosinophilia (6). Antibody against IL-5 abrogates 
parasite-induced eosinophilia (7) suggesting a pivotal role for 
IL-5 in eosinophilia. 
A part of this work was presented at the 49th annual meeting of the 
American  Academy  of Allergy  and Immunology,  Chicago,  IL, March 12-17, 
1993. 
Although there has been significant progress in our un- 
derstanding of factors that control growth and survival of 
eosinophils, the mechanism of homeostatic regulation of these 
events is largely unknown. We hypothesize that the growth 
and survival of eosinophils are physiologically downregulated 
by endogenous factors. Transforming growth factor ~ (TGF-B) 
is a pleiotropic cytokine that promotes the function of resi- 
dent tissue cells but largely inhibits the growth and activity 
of invading inflammatory cells (reviewed in reference 8). TGF-~ 
has been shown to inhibit the differentiation of eosinophils 
from bone marrow cells (9). The effect of TGF-~ on mature 
eosinophils is unknown. The objective of this study was to 
investigate whether TGF-fl could inhibit eosinophil survival 
and promote apoptosis. 
Materials  and  Methods 
Polyvinylpyrrolidone-r  silica gel (Percol]) was purchased 
from Pharmacia LKB (Piscataway, NJ).  Aniline blue, propidium 
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o-phenylenediamine dihydrochloride were from Sigma Chemical 
Co. (St. Louis, MO). IL-3, Ib5, and GM-CSF were purchased from 
Pepro Tech,  Inc.  (Rocky Hill,  NJ).  TGF-B1 was obtained from 
GIBCO BRL (Gaithersburg,  MD) and was dissolved  in 0.05 M 
sodium acetate buffer, pH 4.5, with 1% BSA. A monoclonal anti- 
body (IgG1) that neutralizes TGF-~I, -B2, and -~/3 was obtained 
from Genzyme Corp. (Cambridge, MA). 20/zg/ml of the anti- 
body neutralizes 0.1-0.5 ng/ml of TGF-~. 12SI-GM-CSF (sp act, 
114 #Ci//xg) was purchased from New England Nuclear (Boston, 
MA). ELISA kits for GM-CSF were purchased from R & D Systems, 
Inc. (Minneapolis, MN).  ELISA reagents for IL-5 were obtained 
from the Suntory Institute (Osaka, Japan). FCS was from Hyclone 
Laboratories, Inc. (Logan, UT) and was prescreened for survival 
and cytotoxic activity for eosinophils. 
Purification of Eosinophils.  Eosinophils from normal and allergic 
donors (peripheral blood eosinophil count,  4-8%) were isolated 
by sedimentation with 3% hydroxyethyl starch followed by cen- 
trifugation on a discontinuous PercoU gradient according to Gartner 
(10) as described previously (11). The band at the interface of 1.090 
and 1.10 consisted of eosinophils of 97-99% purity as judged by 
staining with aniline blue (12) and Wright's stain. Eosinophils were 
suspended in  RPMI  1640 with  10%  FCS at a concentration  of 
106/ml. 
Eosinophil SurvivalAssay.  The eosinophil survival assay was car- 
ried out according to a method described previously (13). Purified 
eosinophils were suspended at 106/ml in RPMI 1640 with  10% 
FCS, and cultured in duplicate in multiwell plates (Falcon Labware, 
Oxnard, CA). Eosinophils  were cultured with IL-5 (10-11 M),  IL-3 
(10-10 M), or GM-CSF (10-10 M) with or without TGF-B (10-10 M, 
unless otherwise stated). The viability of the cultured cells on day 
4 was assessed by counting live and dead cells/200 total cells under 
a fluorescence microscope. The counting was done by a trained 
technician who was blinded to the protocol. Eosinophils were stained 
with fluorescein diacetate and propidium iodide for counting live 
and dead cells, respectively (13). In some experiments, eosinophils 
were cultured in the presence of a mouse anti-TGF-B  antibody or 
a control mouse IgG1 antibody. 
Assay of GM-CSF, 11_,5, and TGF-fl.  GM-CSF and TGF-~ were 
measured in eosinophil culture supernatants by using commercially 
available specific ELISA. IL-5 was measured by a sandwich ELISA 
using mouse monoclonal and rabbit polyclonal antibodies as de- 
scribed previously (14). 
Assay of DNA Fragmentation.  The DNA fragmentation assay 
was carried out according to a method described previously (15). 
Eosinophils (1-2  x  106/ml)  were cultured for 72 h  as described 
above, and then pelleted at 4~  The cells were resuspended in 20 
#1 of 10 mM EDTA and 50 mM Tris-HC1, pH 8.0,  containing 
0.5%  sodium lauryl sarkosinate and 0.5  mg/ml of proteinase K 
and incubated for 60 min at 50~  Next, 10/~1 of 10 mM EDTA, 
pH 8.0,  containing 0.25%  bromophenyl blue and 40%  sucrose 
were mixed with each DNA extract. The individual extracts were 
loaded onto 2% agarose gel containing 3/xg/ml of ethidium bro- 
mide. Electrophoresis was performed in 90 mM Tris-HC1, pH 8.3, 
containing 90 mM boric acid and 2.5 mM EDTA until the marker 
dye migrated 6-8 cm. The gel was visualized and photographed 
in UV light with a Polaroid camera. 
Assay of Peroxidase.  Eosinophil peroxidase was measured by a 
colorimetric assay as described by Strath et al. (16). A solution of 
the  substrate  containing  0.1  mM  o-phenylenediamine  dihydro- 
chloride in a 0.05 M Tris buffer, pH 8.0, containing 0.1% Triton 
X-100 and 1 mM hydrogen peroxide was prepared. Purified eo- 
sinophils were preincubated with TGF-~ (10 -1~ M) or buffer for 
10 min and then  stimulated with IL-5 (10  ~0 M)  for 30 min at 
37~  in a water bath. Aliquots (150/~1) of the cell-free superna- 
rants were incubated with 300 #1 substrate solution for 30 min 
at 37~  The reaction was stopped by addition of 200/xl of 4 M 
sulfuric acid. The absorbance was determined at 492 nm by using 
a  spectrophotometer  (Emax;  Molecular  Devices  Corp.,  Menlo 
Park,  CA). 
Binding of ~2SI-GM-CSF  to Eosino?hits.  The binding of ~2SI-GM- 
CSF to eosinophils was performed according to a method described 
previously (17). Eosinophils were suspended in RPMI 1640 +  10% 
FCS at a concentration of 106/ml.  The cells were incubated over- 
night  in  the absence  or presence of TGF-/~ (10-10 M)  and then 
washed twice with HBSS  +  5% FCS at 4~  After incubation 
the cells were suspended in 400 #l of RPMI 1640  +  2 mg/ml of 
BSA.  Next, eosinophils were incubated with various concentra- 
tions of 12SI-GM-CSF (0.5  x  KD-20  x  KD) with or without  a 
50-fold excess of unlabeled GM-CSF for 16 h at 4~  After incuba- 
tion, the cells were suspended and transferred onto 0.75 ml of an 
ice-cold mixture of 75% FCS in RPMI 1640. The cells were cen- 
trifuged for 2 min in a microcentrifuge, and the pellets were sepa- 
rated from the supernatants. The pellets were sliced offwith a razor 
blade for determination of radioactivity. Specific binding was defined 
as the amount of binding blocked by a competition with a 50-fold 
excess unlabeled GM-CSF. 
Data are presented as mean  +  SEM.  Statistical  analyses were 
performed with Wilcoxon signed-rank test for paired samples by 
using the software "Epistat" (Tracy Gustafson, Round Rock, TX). 
Results 
Eosinophil Survival Assay.  The effect of TGF-/3 was studied 
in the eosinophil  survival assay. We found that TGF-~ in- 
hibited eosinophil survival in a dose-dependent manner (Fig. 
1 A).  At a concentration of >/10-12 M  TGF-/~ significantly 
<0.01)  abrogated  eosinophil  survival.  Kinetics  studies 
showed that TGF-/8 exerted its maximal effect within 24 h 
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Figure  1.  (A) The effect of TGF-/~ on eosinopbil survival. Purified eo- 
sinophils (>97%) were cultured in the presence of various concentrations 
of TGF-B with added Ib3 (10-10 M). Live and dead cells were counted 
on day 4. Results of five different experiments are shown. The difference 
in survival is statistically significant (p <0.05) at a concentration of TGF-/~ 
/>10-12 M. (B) The kinetics of the effect of TGF-~ on eosinophil sur- 
vival. Eosinophils were cultured  in the medium alone (NONE), IL-5 
(10 -al M), and IL-5 (10 -I1 M)  +  TGF-B (10 -10 M). The survival was 
assessed every  day for 7 d. Day I represents the start of the culture. Results 
of one of three similar experiments are shown. 
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Inhibition of eosinophil survival by TGF-/~. Eosinophils were 
cultured in the presence of I1.-3 (10-10 M), Ib5 (10-tl M), and GM-CSF 
(10-10 M) with or without TGF-~ (10-10 M). Live and dead cells were 
counted on day 4.  The difference in survival in the presence of TGF-/~ 
is significant (p <  0.01) for IL-3 (n  =  13), IL-5 (n  =  9), and GM-CSF 
(n  =  9). 
(Fig. 1 B). The curve of cell survival in the presence of TGF-/3 
is parallel to that of cells cultured in the absence of IL-5. 
A similar degree of inhibition of eosinophil survival occurred 
when IL-3, IL-5, and GM-CSF were compared as the survival- 
promoting  agents  (Fig.  2).  Anti-TGF-~  antibody  alone 
prolonged the survival of eosinophils (Fig. 3). It also blocked 
the effect of TGF-~/on IL-5-induced eosinophil survival. 
Assay of DNA Fragmentation.  The apoptotic cell death 
of eosinophils was investigated by the assay of DNA frag- 
Figure  4.  Analysis  ofapoptosis 
of eosinophils by agarose gd dec- 
trophoresis. (.4) Eosinophils from 
three donors were cultured for 3 d 
in  the  medium  alone  without 
hematopoietins.  DNA was  iso- 
lated and analyzed  for the presence 
of small molecular  weight frag- 
ments. (B) Eosinophils were cul- 
tured  in  the  presence  of  Ib3 
(10 -10  M)  with  or  without 
TGF-/~ (10-10 M). DNA was iso- 
lated on day 3 and analyzed by gd 
electrophoresis. Results of one of 
three  similar experiments  are 
shown. 
mentation on agarose gel electrophoresis.  DNA was isolated 
from cultured eosinophils on day 3 and was analyzed for the 
presence of small molecular weight fragments ("ladder").  We 
found that TGF-B reversed the inhibitory effect of IL-3 and 
induced DNA fragmentation (Fig.  4). 
Effect of TGF-fl on Eosinophil Function.  We investigated 
the  regulation  of eosinophil  cytokine  synthesis.  We  found 
that IL-3 and GM-CSF stimulated  the synthesis of GM-CSF 
and  IL-5,  respectively  (Fig.  5),  and  TGF-~  significantly  (2 
<0.03)  inhibited  production  of both  GM-CSF  and  IL-5. 
To determine  whether  the inhibitory  effect of TGF-B on 
eosinophil  survival  is  due  to  downregulation  of expression 
of receptors  for hematopoietins,  we  studied  the binding  of 
t2SI-labeled GM-CSF  to eosinophils  after an overnight incu- 
bation with TGF-~. We found that preincubation with TGF-B 
did  not  alter  the  expression  of GM-CSF  receptors  on  eo- 
sinophils  (data  not  shown).  In another  set  of experiments 
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Figure  3.  The effect of a neutralizing anti-TGF-/~ monoclonal antibody 
(IgG1) on eosinophils survival. Eosinophils were cultured alone or in the 
presence of various concentrations  of the antibody with  added TGF-3 
(10-10 M) and/or IL-5 (10-11 M).  The survival was assessed on day 4 (n 
=  4). The anti-TGF-3 antibody significantly prolonged (p <0.05) eosino- 
phil survival. An unrelated  mouse IgG1 antibody that was used in the 
control experiments  did not have any effect on eosinophil  survival. 
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Figure  5.  Production oflL-5 and GM-CSF by eosinophils (.4) and the 
effects of TGF-B (B). (A) Purified eosinophils were cultured in the pres- 
ence of GM-CSF, Ib3 (both 10-10 M), or medium for 24 h. IL-5 and GM- 
CSF were measured in the culture  supernatant  by ELISA. GM-CSF and 
Ib3 significantly (p <0.003)  stimulated  the production of Ib5 (n  =  6) 
and GM-CSF (n =  6), respectively. (B) Eosinophils were cultured as above 
in the presence (+TGF) or absence (-TGF) of TGF-/3 (10-10 M), and then 
Ib5 and GM-CSF were measured in the supernatants. TGF-/~ significantly 
(p <0.03) inhibited the production oflL-5 (n =  6) and GM-CSF (n  =  9). 
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Figure 6.  Inhibition of eosinophil peroxidase release by TGF-/3. Eo- 
sinophils were  incubated  with buffer  or TGF-/~ (10-10 M) for 15 min then 
stimulated with IL-5 (10 -9 M) for 30 min. Peroxidase  was assayed  in the 
supernatant. Results of six duplicate experiments are shown. TGF-/~ 
significantly  ~ <0.03) inhibited the secretion  of peroxidase. Buff,  buffer. 
the effect of TGF-/3 on IL-5-stimulated peroxidase secretion 
was  investigated.  We  found  that  TGF-/3  significantly (p 
<0.03) inhibited the release of peroxidase from eosinophils 
(Fig.  6). 
Discussion 
A number of cytokines regulate growth, function, and sur- 
vival of eosinophils. IL-5, IL-3, and GM-CSF are the most 
important known. All three cytokines enhance the function 
of eosinophils.  Eosinophils become hypodense and primed 
for activation when incubated with these cytokines (18). The 
hematopoietins not only stimulate eosinophilic differentia- 
tion, but also prolong eosinophil survival in vitro. Prolonged 
survival may profoundly contribute to eosinophilia in the tissue 
where the hematopoietins are locally produced. Indeed, in 
vivo studies in patients with eosinophilia showed consider- 
ably prolonged survival (tl/2 =  61 vs. 8-18 h in normal sub- 
jects) of eosinophils (19). 
Some recent reports suggest that eosinophils themselves 
are the source of many cytokines. Eosinophils secrete IL-3 
and  GM-CSF  upon  stimulation  with  calcium ionophore, 
phorbol myristate acetate,  and interferon 3/(20, 21). In situ 
hybridization studies demonstrated the presence of mRNA 
for IL-5 in eosinophils obtained from patients with asthma 
(22) and those with coeliac disease (23).  Thus far, there has 
been no report of secretion of IL-5 by eosinophils. This is 
the first report of production and secretion of IL-5 by eo- 
sinophils. More importantly, we identified physiologic triggers 
for eosinophil production of IL-5 and GM-CSF. We showed 
that  stimulation  of eosinophils  with  one  hematopoietin 
resulted in the production of other hematopoietins. This ob- 
servation may indicate that under some circumstances the 
growth and survival of eosinophils may become independent 
of T cells and other cytokine-producing cells. The hemato- 
poietins produced by eosinophils may work in an autocrine 
and paracrine fashion. 
The results of this study suggest that TGF-/3 is an endog- 
enous negative regulator of eosinophil survival.  TGF-/8 ap- 
pears  to completely abrogate the survival-prolonging effect 
of all hematopoietins, and induces apoptosis. TGF-/3 has been 
shown to cause apoptosis in hepatocytes (24).  One possible 
mechanism of inhibiting eosinophil survival  is that TGF-B 
blocks the synthesis of hematopoietins. TGF-~ has been de- 
tected in eosinophils obtained from patients with eosinophilia 
(25, 26). A neutralizing anti-TGF-~ antibody alone prolongs 
eosinophil survival suggesting an autocrine production of 
TGF-~. We believe that there is a fine balance between the 
production  of TGF-~ and hematopoietins by eosinophils. 
TGF-~ may act as a homeostatic regulatory mechanism that 
counteracts the action of hematopoietins and programs eo- 
sinophils to die. 
TGF-/3 inhibits the function of many cells of the immune 
system including T cells and monocytes. In a previous inves- 
tigation of the effect of TGF-/3 on the expression of receptors 
for IFN-'y on monocytes (27),  TGF-B reduced the expres- 
sion of IFN-3' receptors without altering their affinity.  In 
our study TGF-/3  did not affect GM-CSF receptor expres- 
sion on eosinophils.  Besides inhibiting cytokine synthesis and 
survival,  TGF-/5 blocks the release of eosinophil peroxidase. 
Previously, TGF-/3 has been shown to downregulate the ex- 
pression of CD23  on an eosinophilic cell line,  Eol-1  (28). 
Further, this cytokine inhibits the differentiation of eosinophils 
from bone marrow cells (9). It seems that TGF-B has gener- 
alized inhibitory activity on all aspects of eosinophils including 
growth, differentiation, function, and survival. Thus, the ex- 
ploration of the mechanism of action of TGF-~ on eosinophils 
may provide new avenues for combating eosinophilia associated 
with eosinophilic syndromes and allergic disorders. 
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